Antibiotics and Hydroxychloroquine in Crohn's
Information source: Royal Liverpool University Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Crohn's Disease
Intervention: Ciprofloxacin (Drug); Doxycycline (Drug); Hydroxychloroquine (Drug); Budesonide (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Royal Liverpool University Hospital
Summary
There is growing evidence that Crohn's disease may be caused by replication of bacteria,
perhaps particularly E. coli, within macrophages (a specialized sort of white blood cell).
Laboratory studies show that a combination of antibiotics that can penetrate macrophages
(such as ciprofloxacin and doxycycline) together with the anti-malarial drug
hydroxychloroquine (which makes the contents of macrophage vesicles more alkaline and helps
them to kill intracellular bacteria) is particularly effective at killing the E. coli within
macrophages.
Clinical Details
Official title: A Pilot Randomised Study to Compare Combination Antibiotic Therapy (Ciprofloxacin, Doxycycline and Hydroxychloroquine) With Standard Therapy (Budesonide) in the Treatment of Active Crohn's Disease
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: • Remission, defined as Crohn's Disease activity index (CDAI) <150 at 10 weeks without addition of any other medication or treatment for the Crohn's Disease.• Remission, defined as CDAI ≤150 maintained through to 24 weeks • Remission, defined as CDAI ≤150 maintained through to 52 weeks
Secondary outcome: • Remission defined as CDAI <150 at 4 weeks• Response defined as a fall in CDAI by >70 points at 4 weeks and 10 weeks • Markers of cost (days admitted to hospital, days unable to carry out normal daily activities, need for surgery) • Quality of life at 4 weeks, at 10 weeks, or Early Withdrawal • Patient global assessment of symptom severity by 10 cm visual analogue score at 4 weeks, at 10 weeks, or Early Withdrawal • Adverse Events and possible drug-related side effects: nausea, diarrhoea, mood disturbance, sleep disturbance - will all be assessed at each visit • Fall in Faecal Calprotectin
Detailed description:
Trial Design This is an Open Label Active Study to Compare the Efficacy of 4 weeks
Combination Antibiotic Therapy (Oral Ciprofloxacin 500mg bd plus Doxycycline 100mg bd and
Hydroxychloroquine 200mg tds) followed by a further 20 weeks continued therapy with
Doxycycline 100mg bd and Hydroxychloroquine 200mg tds with Standard Therapy (Oral Budesonide
9mg per day for 8 weeks followed by 6mg per day for 2 weeks and subsequent 3mg per day over
a further 2 weeks) in the treatment of adults with Active Crohn's Disease. Patients who fail
to respond by 10 weeks will be offered the opportunity to cross over onto the alternative
treatment.
Primary endpoint:
- Remission, defined as Crohn's Disease activity index (CDAI) <150 at 10 weeks without
addition of any other medication or treatment for the Crohn's Disease.
- Remission, defined as CDAI ≤150 maintained through to 24 weeks
- Remission, defined as CDAI ≤150 maintained through to 52 weeks
Secondary Endpoints:
- Remission defined as CDAI <150 at 4 weeks
- Response defined as a fall in CDAI by >70 points at 4 weeks and 10 weeks
- Markers of cost (days admitted to hospital, days unable to carry out normal daily
activities, need for surgery)
- Quality of life at 4 weeks, at 10 weeks, or Early Withdrawal
- Patient global assessment of symptom severity by 10 cm visual analogue score at 4
weeks, at 10 weeks, or Early Withdrawal
- Adverse Events and possible drug-related side effects: nausea, diarrhoea, mood
disturbance, sleep disturbance - will all be assessed at each visit
- Fall in Faecal Calprotectin
100 patients will be randomised in order to obtain evaluable population 50 patients per
treatment arm.
6. 1 Informed Consent It is the responsibility of the Investigator to obtain written Informed
Consent from patients before any trial procedure is carried out. All consent documentation
must be in accordance with applicable regulations and GCP. Each patient is requested to
sign the Patient Informed Consent Form after the patient has received and read the written
patient information and received an explanation of what the study involves, including but
not limited to: the objectives, potential benefits and risk, inconveniences and the
subject's rights and responsibilities. A copy of the informed consent documentation
(Consent Form and Subject Information) [Appendix 1] must be given to the patient. A copy
will be retained in the Source Documentation and the original in the Investigator Site File.
Inclusion Criteria (i) Patient is willing to participate in the study and has signed the
informed consent (ii) Patients aged 18 or over with Crohn's disease diagnosed by
conventional clinical, radiological and histological criteria.
(iii) Crohn's disease involving small bowel, colon or both. (iv) Active Crohn's disease:
Crohn's Disease Activity Index (CDAI)> 220 and CRP>10mg/l.
(v) Patients receiving mesalazine (5ASA) must have had a stable dose for at least one month.
(vi) Patients receiving Azathioprine, or Mercaptopurine (who will be separately stratified)
must have had a stable dose for at least 3 months (vii) Women of child bearing potential
must have a negative urine pregnancy test prior to the start of study medication
Exclusion Criteria (i) Patients under 18 or unable to give informed consent. (ii) Any
antibiotic use within the previous 4 weeks (iii) Known sensitivity to Ciprofloxacin,
Doxycycline, Hydroxychloroquine, or Budesonide (iv) Patients with a history of tendon
disorders related to Fluoroquinoline administration (v) Any change to immunosuppressive
therapy (Azathioprine, or Mercaptopurine) within the previous 3 months.
(vi) Use of Infliximab or Adalimumab (anti-TNF antibody) or methotrexate within the previous
3 months (vii) Concurrent use of systemic corticosteroids in excess of oral prednisolone 5
mgs/day or budesonide 3mg/day) (viii) Any change to medication for Crohn's disease in
previous 4 weeks. (ix) Patients with complications requiring surgery (significant intestinal
obstruction, perforation or abscess) (x) CDAI >450 (xi) Participation in other trials in the
last 3 months. (xii) Serious intercurrent infection or other clinically important active
disease (including renal and hepatic disease) (xiii) Pregnant, post-partum (<3months) or
breast feeding females (xiv) Patients with abnormal visual acuity (that does not correct
with glasses) or unexplained visual symptoms (xv) Women of Child Bearing Potential who are
unwilling or unable to use an acceptable method to avoid pregnancy for the entire study
period (double barrier methods such as condoms or diaphragms with spermicidal gel or foam),
and for up to 4 weeks after the study.
(xvi) Patients who need to continue to receive oral contraceptives (if unwilling to use
double barrier methods), oral anticoagulants tricyclic antidepressants, non-steroidal
anti-inflammatory drugs (NSAIDs), anticonvulsants, Sucralfate, or Cyclosporine
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient is willing to participate in the study and has signed the informed consent
- Patients aged 18 or over with Crohn's disease diagnosed by conventional clinical,
radiological and histological criteria.
- Crohn's disease involving small bowel, colon or both.
- Active Crohn's disease: Crohn's Disease Activity Index (CDAI)> 220 and CRP>10mg/l.
- Patients receiving mesalazine (5ASA) must have had a stable dose for at least one
month.
- Patients receiving Azathioprine, or Mercaptopurine (who will be separately
stratified) must have had a stable dose for at least 3 months
- Women of child bearing potential must have a negative urine pregnancy test prior to
the start of study medication
Exclusion Criteria:
- Patients under 18 or unable to give informed consent.
- Any antibiotic use within the previous 4 weeks
- Known sensitivity to Ciprofloxacin, Doxycycline, Hydroxychloroquine, or Budesonide
- Patients with a history of tendon disorders related to Fluoroquinoline administration
- Any change to immunosuppressive therapy (Azathioprine, or Mercaptopurine) within the
previous 3 months.
- Use of Infliximab or Adalimumab (anti-TNF antibody) or methotrexate within the
previous 3 months
- Concurrent use of systemic corticosteroids in excess of oral prednisolone 5 mgs/day
or budesonide 3mg/day)
- Any change to medication for Crohn's disease in previous 4 weeks.
- Patients with complications requiring surgery (significant intestinal obstruction,
perforation or abscess)
- CDAI >450
- Participation in other trials in the last 3 months.
- Serious intercurrent infection or other clinically important active disease
(including renal and hepatic disease)
- Pregnant, post-partum (<3months) or breast feeding females
- Patients with abnormal visual acuity (that does not correct with glasses) or
unexplained visual symptoms
- Women of Child Bearing Potential who are unwilling or unable to use an acceptable
method to avoid pregnancy for the entire study period (double barrier methods such as
condoms or diaphragms with spermicidal gel or foam), and for up to 4 weeks after the
study.
- Patients who need to continue to receive oral contraceptives (if unwilling to use
double barrier methods), oral anticoagulants tricyclic antidepressants, non-steroidal
anti-inflammatory drugs (NSAIDs), anticonvulsants, Sucralfate, or Cyclosporine
Locations and Contacts
Royal Liverpool and Broadgreen Unversity Hospitals Trust, Liverpool, Merseyside L7 8XP, United Kingdom; Recruiting Kate Martin, SRN, Phone: 0151 706 4074, Email: kate.martin@rluhbt.nhs.uk Jonathan M Rhodes, MD, Sub-Investigator Sreedar Subramanian, MD, Principal Investigator
Additional Information
Starting date: January 2013
Last updated: June 26, 2014
|